Ranked by reported Q2 2026 13F market value
Share of total reported institutional value in CRDF held by the largest 10 / 25 filers.
| # | Institution | Shares Held | Market Value | QoQ Change | Ownership % | % of Fund |
|---|---|---|---|---|---|---|
| 1 | Laurion Capital Management LP | 3.1M | $4.0M | +17.1% | 4.020% | 0.10% |
| 2 | VANGUARD CAPITAL MANAGEMENT LLC | 2.9M | $3.8M | +1.4% | 3.757% | 0.00% |
| 3 | PFIZER INC | 2.4M | $3.0M | 0.0% | 3.129% | 1.77% |
| 4 | FRANKLIN TEMPLETON INC | 1.2M | $1.6M | 0.0% | 1.565% | 0.00% |
| 5 | BlackRock, Inc. | 973K | $1.3M | -75.6% | 1.262% | 0.00% |
| 6 | BLAIR WILLIAM & CO/IL | 913K | $1.2M | -1.1% | 1.184% | 0.00% |
| 7 | GEODE CAPITAL MANAGEMENT, LLC | 820K | $1.1M | -48.7% | 1.064% | 0.00% |
| 8 | JANE STREET GROUP, LLC | 689K | $896K | +1617.7% | 0.894% | 0.00% |
| 9 | UBS Group AG | 639K | $830K | +59.5% | 0.829% | 0.00% |
| 10 | VANGUARD FIDUCIARY TRUST CO | 411K | $534K | -8.0% | 0.533% | 0.00% |
| 11 | AQR CAPITAL MANAGEMENT LLC | 346K | $450K | +423.5% | 0.449% | 0.00% |
| 12 | STATE STREET CORP | 331K | $431K | -72.1% | 0.430% | 0.00% |
| 13 | FLPUTNAM INVESTMENT MANAGEMENT CO | 247K | $322K | -58.4% | 0.321% | 0.00% |
| 14 | MORGAN STANLEY | 246K | $320K | +337.1% | 0.319% | 0.00% |
| 15 | BNP PARIBAS FINANCIAL MARKETS | 228K | $297K | +1647.2% | 0.296% | 0.00% |
| 16 | CITADEL ADVISORS LLC | 197K | $257K | -44.3% | 0.256% | 0.00% |
| 17 | MARSHALL WACE, LLP | 162K | $211K | — | 0.211% | 0.00% |
| 18 | Bank of New York Mellon Corp | 162K | $210K | -46.7% | 0.210% | 0.00% |
| 19 | NORTHERN TRUST CORP | 153K | $199K | -69.0% | 0.198% | 0.00% |
| 20 | Avestar Capital, LLC | 136K | $177K | 0.0% | 0.177% | 0.01% |
| 21 | MILLENNIUM MANAGEMENT LLC | 135K | $175K | +484.1% | 0.174% | 0.00% |
| 22 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 127K | $166K | -70.0% | 0.165% | 0.00% |
| 23 | Qube Research & Technologies Ltd | 126K | $163K | — | 0.163% | 0.00% |
| 24 | GOLDMAN SACHS GROUP INC | 121K | $157K | -10.9% | 0.157% | 0.00% |
| 25 | AlphaCore Capital LLC | 108K | $141K | +0.1% | 0.141% | 0.00% |
denotes a marquee investor (Buffett, Burry, ARK, Tiger Global, Pershing Square, Baupost and other widely-followed managers). “% of Fund” shows how much of that investor’s total 13F portfolio is invested in CRDF — a direct measure of their conviction.
Filings activity in CRDF during Q2 2026, grouped by how each filer changed its position.
8 quarters of 13F filings · Δ columns show change vs prior quarter
| Quarter | Inst. Holders | Δ Holders | Ownership % | Δ Ownership | Total 13F Value | Δ Value |
|---|---|---|---|---|---|---|
| Q2 2026 | 104 | 11% | 24.66% | 8.05 pp | $24M | 41% |
| Q1 2026 | 117 | +6.4% | 32.71% | 3.63 pp | $40M | 52% |
| Q4 2025 | 110 | 2.7% | 36.34% | +1.29 pp | $84M | +55% |
| Q3 2025 | 113 | 1.7% | 35.05% | 4.23 pp | $55M | 40% |
| Q2 2025 | 115 | +0.0% | 39.28% | 3.76 pp | $91M | 7.7% |
| Q1 2025 | 115 | +0.9% | 43.04% | +5.55 pp | $99M | 17% |
| Q4 2024 | 114 | +43% | 37.49% | +15.99 pp | $119M | +290% |
| Q3 2024 | 80 | — | 21.50% | — | $30M | — |
Source: SEC 13F institutional filings. Ownership % requires market cap data and will show once linked. Δ columns compare to the immediately prior filed quarter.
Latest Form 4 transactions by company officers and directors. Insider buys are widely viewed as a key fundamental indicator because executives are risking personal capital.
| Date | Insider | Action | Shares | Price | Value |
|---|---|---|---|---|---|
| Jun 18, 2026 | Mohindru Mani | Buy | 25K | $1.21 | $30K |
Institutional ownership and quarterly buying activity across the largest Oncology Biotech peers.
Quick answers to the most common questions about buying CRDF stock.
Based on Q2 2026 13F filings, institutional ownership of Cardiff Oncology, Inc. stands at 24.7%, held across 104 reporting institutions.
Laurion Capital Management LP is the largest reported institutional holder of CRDF, with approximately 3,098,299 shares worth $0.00B as of Q2 2026.
Yes — 4 widely-followed marquee investors appear among the top 25 institutional holders of CRDF, including JANE STREET GROUP, LLC, CITADEL ADVISORS LLC, MILLENNIUM MANAGEMENT LLC, SUSQUEHANNA INTERNATIONAL GROUP, LLP.
Our composite Smart Money Score for CRDF is 43 out of 100 (Neutral). It combines net institutional buying activity, ownership shift, marquee investor presence, and holder-count growth.
18 institutions opened new positions in CRDF during Q2 2026, while 29 fully exited. 22 added to existing positions and 63 trimmed.
CRDF institutional ownership fell by 8.05 percentage points quarter-over-quarter, with a net change of -13 holders.
The top 10 institutions account for 76.7% of all reported 13F value in CRDF, and the top 25 account for 92.3%.
Across the largest Oncology Biotech peers, institutional ownership levels are: DMRA (200.0%), FTH (54.5%), LONA (184.4%), KYNB (26.9%), CNSY (4.8%). See the peer comparison table on this page for net buyer activity by company.
All data is sourced from SEC Form 13F filings, which institutional investment managers with at least $100M in assets are required to file each quarter. We process every 13F filing from EDGAR and recompute the aggregates after each cycle. Insider transactions are sourced from Form 4 filings.